Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes

Diabetic Medicine

Volumn 22, Issue 8, 2005, Pages 1016-1023

  Feinglos, Mark N ^a   Saad, M F ^b   Pi Sunyer, F X ^c   An, B ^d   Santiago, O ^d  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^d NOVO NORDISK INC   (United States)

Author keywords

cell; Dose response; GLP 1; Secretagogue; Weight

Indexed keywords

HEMOGLOBIN A1C; LIRAGLUTIDE; METFORMIN; ORAL ANTIDIABETIC AGENT;

ADULT; AGED; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; VOMITING;

ADULT; AGED; BLOOD GLUCOSE; BODY MASS INDEX; BODY WEIGHT; DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED;

EID: 22644444292     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2005.01567.x     Document Type: Article

References (31)

1. Orskov C. Glucagon-like peptide-1, a new hormone of the entero-insular axis. Diabetologia 1992; 35: 701-711.
2. Larsson H, Holst JJ, Ahren B. Glucagon-like peptide-1 reduces hepatic glucose production indirectly through insulin and glucagon in humans. Acta Physiol Scand 1997; 160: 413-422.
3. Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998; 101: 515-520.
4. Gutzwiller JP, Goke B, Drewe J, Hildebrand P, Ketterer S, Handschin D et al. Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut 1999; 44: 81-86.
5. Naslund E, Gutniak M, Skogar S, Rossner S, Hellstrom PM. Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men. Am J Clin Nutr 1998; 68: 525-530.
6. Naslund E, Gryback P, Backman L, Jacobsson H, Holst JJ, Theodorsson E et al. Distal small bowel hormones: correlation with fasting antroduodenal motility and gastric emptying. Dig Dis Sci 1998; 43: 945-952.
7. Ranganath LR, Beety JM, Morgan LM, Wright JW, Howland R, Marks V. Attenuated GLP-1 secretion in obesity: cause or consequence? Gut 1996; 38: 916-919.
8. Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CM, Meeran K et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996; 379: 69-72.
9. Mannucci E, Ognibene A, Cremasco F, Bardini G, Mencucci A, Pierazzuoli E et al. Glucagon-like peptide (GLP)-1 and leptin concentrations in obese patients with Type 2 diabetes mellitus. Diabet Med 2000; 17: 713-719.
10. Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 1995; 80: 952-957.
11. Deacon CF, Knudsen LB, Madsen K, Wiberg FC, Jacobsen O, Holst JJ. Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity. Diabetologia 1998; 41: 271-278.
12. Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36) amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 1993; 214: 829-835.
13. Knudsen LB, Nielsen PF, Huusfeldt PO, Johansen NL, Madsen K, Pedersen FZ et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem 2000; 43: 1664-1669.
14. Ribel U, Larsen MO, Rolin B, Carr RD, Wilken M, Sturis J et al. NN2211: a long-acting glucagon-like peptide-1 derivative with anti-diabetic effects in glucose-intolerant pigs. Eur J Pharmacol 2002; 451: 217-225.
15. Chang AM, Jakobsen G, Sturis J, Smith MJ, Bloem CJ, An B et al. The GLP-1 derivative NN2211 restores β-cell sensitivity to glucose in Type 2 diabetic patients after a single dose. Diabetes 2003; 52: 1786-1791.
16. Degn KB, Juhl CB, Sturis J, Jakobsen G, Brock B, Chandramouli V et al. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and α- and β-function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 2004; 53: 1187-1194.
17. Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews D. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211). Diabetes Care 2004; 27: 1335-1342.
18. Larsen PJ, Fledelius C, Knudsen LB, Tang-Christensen M. Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats. Diabetes 2001; 50: 2530-2539.
19. Benthem L, Wei. L, Lange KZ, Knudsen LB. The long-acting GLP-1 derivative NN2211 improves glucose tolerance and normalizes body weight in diet induced obese rats. Diabetes 2002; 51: A338.
20. Hansen BC, Bjenning C, Knudsen LB. Sustained appetite suppression and weight loss in obese rhesus monkeys treated with a long-acting GLP-1 derivative, NN2211. Diabetologia 2001; 44: A196.
21. Raun K, Von Voss P, Ankersen TR, Bollen P, Knudsen LB. The GLP-1 derivative NN2211 normalizes food intake and lowers body weight in a hyperphagic minipig model. Diabetes 2003; 52: A325.
22. Garber AJ, Duncan TG, Goodman AM, Mills DJ, Rohlf JL. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med 1997; 103: 491-497.
23. Yki-Jarvinen H, Nikkila K, Makimattila S. Metformin prevents weight gain by reducing dietary intake during insulin therapy in patients with type 2 diabetes mellitus. Drugs 1999; 58: 53-54.
24. American Diabetes Association. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2000; 23: S4-19.
25. Bertin E, Marcus C, Ruiz JC, Eschard JP, Leutenegger M. Measurement of visceral adipose tissue by DXA combined with anthropometry in obese humans. Int J Obes Relat Metab Disord 2000; 24: 263-270.
26. Holst JJ. Therapy of type 2 diabetes mellitus based on the actions of glucagon- like peptide-1. Diabetes Metab Res Rev 2002; 18: 430-441.
27. Meier JJ, Gallwitz B, Schmidt WE, Nauck MA. Glucagon-like peptide 1 as a regulator of food intake and body weight: therapeutic perspectives. Eur J Pharmacol 2002; 440: 269-279.
28. Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy uptake in humans. J Clin Invest 1998; 101: 515-520.
29. Elbrond B, Jakobsen G, Larsen S, Agerso H, Jensen LB, Rolan P et al. Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. Diabetes Care 2002; 25: 1398-1404.
30. Gromada J, Holst JJ, Rorsman P. Cellular regulation of islet hormone secretion by the incretin hormone glucagon-like peptide 1. Pflugers Arch 1998; 435: 583-594.
31. Nauck MA, El-Ouaghlidi A, Homepesch M, Jacobsen J, Elbroend B. No impairment of hypoglycemia counterregulation via glucagon with NN2211, a GLP-1 derivative, in subjects with type 2 diabetes. Diabetes 2003; 52: A128.